259 related articles for article (PubMed ID: 35265213)
1. A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.
Wang X; Sun R; Wang J; Li J; Walker E; Shirke A; Ramamurthy G; Shan L; Luo D; Carmon L; Basilion JP
Theranostics; 2022; 12(5):2335-2350. PubMed ID: 35265213
[No Abstract] [Full Text] [Related]
2. Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen.
Wang X; Tsui B; Ramamurthy G; Zhang P; Meyers J; Kenney ME; Kiechle J; Ponsky L; Basilion JP
Mol Cancer Ther; 2016 Aug; 15(8):1834-44. PubMed ID: 27297866
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
4. A PSMA-targeted theranostic agent for photodynamic therapy.
Chen Y; Chatterjee S; Lisok A; Minn I; Pullambhatla M; Wharram B; Wang Y; Jin J; Bhujwalla ZM; Nimmagadda S; Mease RC; Pomper MG
J Photochem Photobiol B; 2017 Feb; 167():111-116. PubMed ID: 28063300
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.
Wang X; Shirke A; Walker E; Sun R; Ramamurthy G; Wang J; Shan L; Mangadlao J; Dong Z; Li J; Wang Z; Schluchter M; Luo D; Wang Y; Stauffer S; Brady-Kalnay S; Hoimes C; Lee Z; Basilion JP
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499427
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
7. Comparison of low-molecular-weight ligand and whole antibody in prostate-specific membrane antigen targeted near-infrared photoimmunotherapy.
Nakajima K; Miyazaki F; Terada K; Takakura H; Suzuki M; Ogawa M
Int J Pharm; 2021 Nov; 609():121135. PubMed ID: 34571072
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
[TBL] [Abstract][Full Text] [Related]
9. Old Drug, New Delivery Strategy: MMAE Repackaged.
Lahnif H; Grus T; Salvanou EA; Deligianni E; Stellas D; Bouziotis P; Rösch F
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239890
[TBL] [Abstract][Full Text] [Related]
10. Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.
Nagaya T; Nakamura Y; Okuyama S; Ogata F; Maruoka Y; Choyke PL; Kobayashi H
Mol Cancer Res; 2017 Sep; 15(9):1153-1162. PubMed ID: 28588059
[TBL] [Abstract][Full Text] [Related]
11. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?
Watanabe R; Hanaoka H; Sato K; Nagaya T; Harada T; Mitsunaga M; Kim I; Paik CH; Wu AM; Choyke PL; Kobayashi H
J Nucl Med; 2015 Jan; 56(1):140-4. PubMed ID: 25500827
[TBL] [Abstract][Full Text] [Related]
12. PSMA-targeted melanin-like nanoparticles as a multifunctional nanoplatform for prostate cancer theranostics.
Dai L; Shen G; Wang Y; Yang P; Wang H; Liu Z
J Mater Chem B; 2021 Jan; 9(4):1151-1161. PubMed ID: 33434248
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors.
Lütje S; Heskamp S; Franssen GM; Frielink C; Kip A; Hekman M; Fracasso G; Colombatti M; Herrmann K; Boerman OC; Gotthardt M; Rijpkema M
Theranostics; 2019; 9(10):2924-2938. PubMed ID: 31244933
[No Abstract] [Full Text] [Related]
14. Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
Derks YHW; Schilham MGM; Rijpkema M; Smeets EMM; Amatdjais-Groenen HIV; Kip A; van Lith SAM; van de Kamp J; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Heskamp S; Lütje S
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2872-2884. PubMed ID: 37060367
[TBL] [Abstract][Full Text] [Related]
15. Targeted Chemoradiotherapy of Prostate Cancer Using Gold Nanoclusters with Protease Activatable Monomethyl Auristatin E.
Luo D; Wang X; Walker E; Springer S; Ramamurthy G; Burda C; Basilion JP
ACS Appl Mater Interfaces; 2022 Apr; 14(13):14916-14927. PubMed ID: 35316026
[TBL] [Abstract][Full Text] [Related]
16. Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer.
Derks YHW; van Lith SAM; Amatdjais-Groenen HIV; Wouters LWM; Kip A; Franssen GM; Laverman P; Löwik DWPM; Heskamp S; Rijpkema M
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2425-2435. PubMed ID: 35029739
[TBL] [Abstract][Full Text] [Related]
17. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
18. A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile.
Boinapally S; Ahn HH; Cheng B; Brummet M; Nam H; Gabrielson KL; Banerjee SR; Minn I; Pomper MG
Sci Rep; 2021 Mar; 11(1):7114. PubMed ID: 33782486
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a photodynamic therapy agent using a canine prostate cancer model.
Luo D; Wang X; Ramamurthy G; Walker E; Zhang L; Shirke A; Naidu NG; Burda C; Shakya R; Hostnik ET; Joseph M; Ponsky L; Ponomarev V; Rosol TJ; Tweedle MF; Basilion JP
Prostate; 2023 Sep; 83(12):1176-1185. PubMed ID: 37211857
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
